Floatz logo

Vtx-2337

Ovarian Clear Cell Cystadenocarcinoma

Gynecologic Oncology GroupPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Ovarian Clear Cell Cystadenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 2BB
FILGRASTIM
University of Washington
Phase 2B
Docetaxel
National Cancer Institute (NCI)
Phase 2B
Hycamtin
Gynecologic Oncology Group
Phase 2B
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2B

View all 23 →

Same molecule, other indications

Vtx-2337 is also rated in:

ovarian carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
primary peritoneal carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
fallopian tube cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →